What Corvus Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 3 |
| Sells | 0 | 0 |
| Total trades | 0 | 16 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 238,632 |
| Disposed | 0 | 0 |
| Net activity | +0 | +238,632 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Moore David Scott | Director | Jun 11 | Open-market buy · P | +21,700 | $11.53 | +$250K | 21,700 |
| Miller Richard A Md | President and CEO | May 18 | Open-market buy · P | +1,932 | $12.01 | +$23.2K | 1,195,035 |
| Miller Richard A Md | President and CEO | May 18 | Open-market buy · P | +5,000 | $12.05 | +$60.3K | 1,193,103 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $2.12 | +$31.8K | 210,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $1.64 | +$24.6K | 195,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $2.49 | +$37.4K | 180,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $0.97 | +$14.5K | 165,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $0.99 | +$14.8K | 150,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $2.60 | +$39K | 135,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $2.74 | +$41.1K | 120,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $3.27 | +$49.1K | 105,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $2.00 | +$30K | 90,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $3.61 | +$54.2K | 75,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $12.50 | +$188K | 60,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +15,000 | $9.70 | +$146K | 45,000 |
| Thompson Peter A | Director | Jan 28 | Exercise / conversion · M | +30,000 | $15.00 | +$450K | 30,000 |
| Orbimed Advisors Llc | Director | Jun 27 | Open-market sale · S | −1,176,332 | $4.16 | −$4.89M | 7,165,006 |
| Orbimed Advisors Llc | Director | Jun 27 | In/At-money Exercise · X | +1,397,684 | $3.50 | +$4.89M | 8,341,338 |
| Thompson Peter A | Director | Jun 27 | Open-market sale · S | −1,176,332 | $4.16 | −$4.89M | 7,165,006 |
| Thompson Peter A | Director | Jun 27 | In/At-money Exercise · X | +1,397,684 | $3.50 | +$4.89M | 8,341,338 |
Loading...
